EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study

Naokatsu Ando iD, Daisuke Mizushima iD, Misao Takano, Morika Mitobe, Kai Kobayashi, Hiroaki Kubota iD, Hirofumi Miyake, Jun Suzuki, Kenji Sadamasu, Takahiro Aoki, Koji Watanabe iD, Haruka Uemura und 3 weitere

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad208 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Naokatsu Ando und 14 weiteren Autor:innen. Beteiligte Einrichtung: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Mycoplasma genitalium, Mycoplasma Infections, Quinolones. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Center for Global Health and Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycoplasma genitalium has a tendency to develop macrolide and quinolone resistance.

Objectives

We investigated the microbiological cure rate of a 7 day course of sitafloxacin for the treatment of rectal and urogenital infections in MSM. Patients and methods This open-label, prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan from January 2019 to August 2022. Patients with M. genitalium urogenital or rectal infections were included. The patients were treated with sitafloxacin 200 mg daily for 7 days. M. genitalium isolates were tested for parC, gyrA and 23S rRNA resistance-associated mutations.

Results

In total, 180 patients (median age, 35 years) were included in this study, of whom 77.0% (97/126) harboured parC mutations, including 71.4% (90/126) with G248T(S83I) in parC, and 22.5% (27/120) harboured gyrA mutations. The median time to test of cure was 21 days. The overall microbiological cure rate was 87.8%. The cure rate was 100% for microbes harbouring parC and gyrA WTs, 92.9% for microbes harbouring parC G248T(S83I) and gyrA WT, and 41.7% for microbes harbouring parC G248T(S83I) and gyrA with mutations. The cure rate did not differ significantly between urogenital and rectal infection (P = 0.359).

Conclusions

Sitafloxacin monotherapy was highly effective against infection caused by M. genitalium, except strains with combined parC and gyrA mutations. Sitafloxacin monotherapy can be used as a first-line treatment for M. genitalium infections in settings with a high prevalence of parC mutations and a low prevalence of gyrA mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycoplasma genitaliumMycoplasma InfectionsQuinolonesHumansAdultProspective StudiesDNA Topoisomerase IVDrug Resistance, BacterialFluoroquinolonesAnti-Bacterial AgentsMutationMacrolidesPrevalence

Substanzen

sitafloxacinQuinolonesDNA Topoisomerase IVFluoroquinolonesAnti-Bacterial AgentsMacrolides

Autor:innen und Institutionen

  • AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

ORCID-Profile: Naokatsu Ando, Daisuke Mizushima, Hiroaki Kubota, Koji Watanabe, Yasuaki Yanagawa

Förderung

  • National Center for Global Health and Medicine

Zitieren

APA

Ando, N., Mizushima, D., Takano, M., Mitobe, M., Kobayashi, K., Kubota, H., Miyake, H., Suzuki, J., Sadamasu, K., Aoki, T., Watanabe, K., Uemura, H., Yanagawa, Y., Gatanaga, H., & Oka, S. (2023). Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad208

Vancouver

Ando N, Mizushima D, Takano M, Mitobe M, Kobayashi K, Kubota H, et al. Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad208

BibTeX
@article{Ando2023,
  author = {Ando, Naokatsu and Mizushima, Daisuke and Takano, Misao and Mitobe, Morika and Kobayashi, Kai and Kubota, Hiroaki and Miyake, Hirofumi and Suzuki, Jun and Sadamasu, Kenji and Aoki, Takahiro and Watanabe, Koji and Uemura, Haruka and Yanagawa, Yasuaki and Gatanaga, Hiroyuki and Oka, Shinichi},
  title = {Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad208}
}
Kostenlos starten →